Hendrick Tan (@hendo_tan) 's Twitter Profile
Hendrick Tan

@hendo_tan

Radiation Oncologist @PerthWA | MR-Linac RadOnc | Former Clinical Fellow @Sunnybrook | Advocate for #radonc | Basketball enthusiast⛹️ | Views=own 🇦🇺

ID: 921211391897300993

calendar_today20-10-2017 03:08:05

1,1K Tweet

790 Followers

749 Following

Joe Y Chang (@joechangmd) 's Twitter Profile Photo

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

Re-irradiation is common but challenging in lung cancer. 
ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary.
My personalized Share Link:
authors.elsevier.com/c/1l3k51Hx52Ni…
Rohit Malde (@roxboxfix) 's Twitter Profile Photo

First RCT comparing Hypofractionated Versus Single-Session Radiosurgery to Preserve Hearing in Patients Affected by Sporadic Vestibular Schwannoma

First RCT comparing Hypofractionated Versus Single-Session Radiosurgery to Preserve Hearing in Patients Affected by Sporadic Vestibular Schwannoma
MR-Linac Consortium (@mr_linac) 's Twitter Profile Photo

Sun Yat-sen University Cancer Centre report promising results for online hypo-fractionated adaptive MRgRT in treating brain metastases in non-small cell lung cancer. thelancet.com/journals/eclin… # progressthroughcollaboration Research@TheBrainTumourCharity

PDBrown (@pdbrownonc) 's Twitter Profile Photo

🚨 Randomized Trial: Significantly less symptom burden with SRS compared to HA-WBRT. SRS Standard of Care for 5-20 brain mets 🚨🚨🚨

🚨 Randomized Trial: Significantly less symptom burden with SRS compared to HA-WBRT. 
SRS Standard of Care for 5-20 brain mets 🚨🚨🚨
Mark V. Mishra (@markmishramd) 's Twitter Profile Photo

#ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rates (52% vs 30%) vs chemo alone in Phase III trial (N=124). First RCT evidence favoring NACRT in this tough-to-treat disease #radonc 🔗 meetings.asco.org/abstracts-pres…

Mark V. Mishra (@markmishramd) 's Twitter Profile Photo

#ASCO25 Final CATNON trial results confirm: adjuvant TMZ (not concurrent) improves OS in IDH-mut anaplastic glioma (12.5 yrs vs 1.7 yrs in IDHwt). No added benefit from concurrent TMZ. RT→adjTMZ remains standard for IDHmt, 1p/19q-intact disease #btsm 🔗 meetings.asco.org/abstracts-pres…

Mark V. Mishra (@markmishramd) 's Twitter Profile Photo

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗 meetings.asco.org/abstracts-pres…

International Consortium on Meningiomas (ICOM) (@icomeningioma) 's Twitter Profile Photo

DOTATATE PET/MR represents a promising #ImagingBiomarker for response assessment in #meningiomas treated with #radiosurgery - this was the important finding from a recent study. Read about it now in #NeuroOncology: academic.oup.com/neuro-oncology…

DOTATATE PET/MR represents a promising #ImagingBiomarker for response assessment in #meningiomas treated with #radiosurgery - this was the important finding from a recent study. 

Read about it now in #NeuroOncology: academic.oup.com/neuro-oncology…
Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

Come on #ASCO25, this 💯 should have been a plenary! 7% improvement in 8-yr OS w exercise in adjuvant colon ca, greater than benefit for adding oxali to 5-FU (5% at 10 yrs in MOSAIC). Exercise = $ effective, ~0 tox, & gives pts sense of empowerment. Congrats Chris Booth et al!

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

Landmark OS data from #CheckMate816 just dropped in NEJM! 🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers: ✅ 5-yr OS: 65.4% vs 55.0% ✅ HR: 0.72 (p=0.048) ✅ Lung cancer–specific survival HR: 0.65 ✅ OS with pCR: 95.3% ✅ ctDNA clearers: 75%+ OS 📌 No lung

Landmark OS data from #CheckMate816 just dropped in <a href="/NEJM/">NEJM</a>!
🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers:
✅ 5-yr OS: 65.4% vs 55.0%
✅ HR: 0.72 (p=0.048)
✅ Lung cancer–specific survival HR: 0.65
✅ OS with pCR: 95.3%
✅ ctDNA clearers: 75%+ OS
📌 No lung
Adela (@adelapoite) 's Twitter Profile Photo

Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in Glioblastoma - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…

ASTRO (@astro_org) 's Twitter Profile Photo

Read this new #RedJournal article from Istituto Neurologico Carlo Besta on hypofractionated radiosurgery, 25 Gy in 5 fractions, for optic nerve sheath meningiomas. #radonc tinyurl.com/marchettired

Read this new #RedJournal article from <a href="/NeuroBesta/">Istituto Neurologico Carlo Besta</a> on hypofractionated radiosurgery, 25 Gy in 5 fractions, for optic nerve sheath meningiomas. #radonc tinyurl.com/marchettired
Ethan Ludmir MD (@ebludmir) 's Twitter Profile Photo

Chad Tang, MD & I happy to report: ph2 basket EXTEND-OP trial has enrolled and randomized 150 patients in the last year since opening: - 7 histology-specific baskets - Oligoprogressive dz randomized to: ☢ Local Tx + continued same-line systemic, versus 💊Switching systemic Tx

<a href="/ChadTangMD/">Chad Tang, MD</a> &amp; I happy to report: ph2 basket EXTEND-OP trial has enrolled and randomized 150 patients in the last year since opening:
- 7 histology-specific baskets
- Oligoprogressive dz randomized to: 
☢ Local Tx + continued same-line systemic, versus 💊Switching systemic Tx
ISRSy (@isrsy) 's Twitter Profile Photo

ANNOUNCING: The next #ISRSWebinar📣 “SBRT for Non-Spine Bone Metastases – A Review of Recent Literature & Guidelines” 🗓️ Wed, 30 July 2025, 2PM CET 🥼Timothy Nguyen, MD, FRCPC Tim Nguyen This webinar will review recent publications on SBRT for NSBM and recent consensus

ANNOUNCING: The next #ISRSWebinar📣

“SBRT for Non-Spine Bone Metastases – A Review of Recent Literature &amp; Guidelines”

🗓️ Wed, 30 July 2025, 2PM CET
🥼Timothy Nguyen, MD, FRCPC
<a href="/TimkWin/">Tim Nguyen</a> 

This webinar will review recent publications on SBRT for NSBM and recent consensus
ASTRO (@astro_org) 's Twitter Profile Photo

New in #practicalRO: Identification of Key Anatomical Structures on MRI During Prostate Stereotactic Body Radiotherapy For Dose Avoidance to Reduce Erectile Dysfunction Risk #radonc tinyurl.com/prozelefsky

New in #practicalRO: Identification of Key Anatomical Structures on MRI During Prostate Stereotactic Body Radiotherapy For Dose Avoidance to Reduce Erectile Dysfunction Risk #radonc tinyurl.com/prozelefsky